Systemic therapies and cognitive impairment for breast cancer: an overview of the current literature

被引：10

作者：

Meattini, Icro ^{[1
]}

Desideri, Isacco ^{[1
]}

Francolini, Giulio ^{[1
]}

Vannini, Agnese ^{[1
]}

Perna, Marco ^{[1
]}

Garlatti, Pietro ^{[1
]}

Grassi, Roberta ^{[1
]}

Livi, Lorenzo ^{[1
]}

机构：

[1] Univ Florence, Azienda Osped Univ Careggi, Largo GA Brambilla 3, I-50134 Florence, Italy

来源：

MEDICAL ONCOLOGY | 2017年 / 34卷 / 05期

关键词：

Cognitive impairment; Systemic therapy; Endocrine therapy; Breast cancer; Quality of life; STANDARD-DOSE CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; ENDOCRINE THERAPY; OLDER PATIENTS; FEATURES; 10; SURVIVORS; WOMEN; METAANALYSIS; MULTICENTER; TAMOXIFEN;

D O I：

10.1007/s12032-017-0935-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Both endocrine and chemotherapy can be utilized for breast cancer patients' management, in multiple setting (i.e., primary systemic therapy, adjuvant, metastatic treatment). Health-related quality of life in breast cancer survivors can be significantly influenced by cognitive impairment, which has been related in several previously reported experiences to systemic therapies administration. However, although the growing body of literature, the impact of both chemo-and endocrine therapy on cognitive function is currently unclear, due to many confounding factors (i.e., multiple therapies, duration of therapy, comorbidity, age). The aim of the present review is to present an overview of the current literature concerning the possible influence of endocrine and systemic therapy on breast cancer patients' cognitive impairment.

引用

页数：8

共 44 条

[1]

Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.20.2.485

[2]

[Anonymous], 2016, Lancet

[3] Cognitive impairment associated with adjuvant therapy in breast cancer [J].